Clinical Impact of the M184V Mutation on Switching to Didanosine or Maintaining Lamivudine Treatment in Nucleoside Reverse‐Transcriptase Inhibitor–Experienced Patients | Zendy

Mark A. Winters | Zendy; Ronald J. Bosch | Zendy; Mary Albrecht | Zendy; David Katzenstein | Zendy

Open Access

Clinical Impact of the M184V Mutation on Switching to Didanosine or Maintaining Lamivudine Treatment in Nucleoside Reverse‐Transcriptase Inhibitor–Experienced Patients

Author(s) -

Mark A. Winters,

Ronald J. Bosch,

Mary Albrecht,

David Katzenstein

Publication year - 2003

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/377742

Subject(s) - didanosine , lamivudine , nucleoside reverse transcriptase inhibitor , resistance mutation , reverse transcriptase inhibitor , reverse transcriptase , virology , nucleoside analogue , stavudine , nucleoside , medicine , human immunodeficiency virus (hiv) , virus , biology , viral disease , viral load , rna , sida , genetics , antiretroviral therapy , hepatitis b virus , gene

Virologic outcome among 104 lamivudine (3TC)-experienced individuals infected with human immunodeficiency virus type 1 who switched to a didanosine (ddI)-containing triple- or quadruple-drug regimen was compared with those who continued receiving a 3TC-containing regimen. A significantly increased independent risk of virologic failure was associated with continuing a 3TC-containing regimen. In addition, most patients for whom the ddI-containing regimen failed lost the M184V/I mutation. These results show that ddI continues to provide activity against viruses with the M184V/I mutation and suggest that the presence of the M184V/I mutation should not preclude the use of ddI in nucleoside-experienced patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research